Growth Metrics

Ptc Therapeutics (PTCT) Common Equity: 2011-2024

Historic Common Equity for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$1.1 billion.

  • Ptc Therapeutics' Common Equity rose 85.23% to -$155.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.8 million, marking a year-over-year increase of 85.23%. This contributed to the annual value of -$1.1 billion for FY2024, which is 34.15% down from last year.
  • Ptc Therapeutics' Common Equity amounted to -$1.1 billion in FY2024, which was down 34.15% from -$818.6 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Common Equity peaked at $482.0 million during FY2020, and registered a low of -$1.1 billion during FY2024.
  • Its 3-year average for Common Equity is -$754.6 million, with a median of -$818.6 million in 2023.
  • Data for Ptc Therapeutics' Common Equity shows a maximum YoY slumped of 24,236.72% (in 2022) over the last 5 years.
  • Ptc Therapeutics' Common Equity (Yearly) stood at $482.0 million in 2020, then crashed by 99.70% to $1.4 million in 2021, then slumped by 24,236.72% to -$347.1 million in 2022, then slumped by 135.84% to -$818.6 million in 2023, then plummeted by 34.15% to -$1.1 billion in 2024.